PrecisionPhage has officially announced the opening of its post-seed funding round, marking a significant step toward scaling advanced genomic and bioinformatics solutions to tackle antimicrobial resistance (AMR). The announcement was made via the company’s official LinkedIn page.
The company is focused on expanding its proprietary Molecular Data Intelligence Platform, a system designed to enhance genomics analysis through the integration of artificial intelligence.
This latest development builds on earlier funding success. In 2024, PrecisionPhage raised a total of €2.2 million, including €1 million in investments from Nordic Science Investment, Genetricum, and Unifund, alongside €1.2 million secured through the Deep Tech Accelerator programme from Business Finland.
To date, the company has delivered key bioinformatics tools, including Phagenomics Core and Phagenomics BatchQC. With the new funding round, PrecisionPhage aims to scale its AI-enabled phage solutions, with a focus on safety and compliance within regulated environments.
